Based on our preclinical studies in rodents and monkeys, which support our hypothesis that F-18 fluoropropylthio-TZTP is an M2 selective ligand, we have filed an Investigational New Drug application (IND) and proceeded to a Phase II human study in collaboration with NIA and NIMH. Five normal subjects have been studied to date with results consistent with M2 receptor binding.We have also developed a series of 18F and 11C labeled antagonists for the 5HT1A and 5HT2A receptor. The compounds tested have high specificity for the receptor class and high receptor specificity for the receptor subtype. Distribution studies in vivo are consistent with 5HT receptor binding. We have chosen for further evaluation two derivatives of WAY 100635 [(N-(2-(1-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridyl) cyclohexane-carboxamide] by replacing the cyclohexane carboxylic acid with either 3-methyl, 4-fluorobenzoic acid (to produce MeFBWAY) or trans 4-fluorocyclohexylcarboxylic acid (to produce FCWAY). MeFBWAY has an inhibition constant of 4 nM, has high brain uptake in rats, and a low non-specific binding fraction. In monkeys, [18F]MeFBWAY approaches transient equilibrium rapidly in all tissues. Because of its rapid kinetics, [18F]MeFBWAY can be infused to equilibrium and readily displaced by an injection of 20 nmol/Kg WAY. Because of the lower Ki, lower contrast is achieved when compared to the higher affinity compound [18F]FCWAY. In monkey studies, transient equilibrium was achieved only by 2 hours after injection of [18F]FCWAY. The regional specific binding pattern was highly correlated with that observed with the parent compound, WAY 100635 and pre- and post-injection of WAY 100635 after injection of [18F]FCWAY confirmed saturable binding. All preclinical work is completed on both compounds. [18F]FCWAY is better suited for the measurement of receptor concentration changes. Whereas, [18F]MeFBWAY is better suited to measure displacement due to changes in endogenous neurotransmitter.We have also done the following:Y Evaluated [C-11]MDL 100,907 as a tracer for 5-HT2A receptors in primates and developed a tracer kinetic model for quantification.Y Developed an optimized strategy and various model-based methods for the measurement of neurotransmitter release with [11C] raclopride.Y Evaluated the brain kinetics of 3 [18F]-labeled acids that are metabolites of the 5HT1A tracers.We have found that an infusion of lysine (Aminosyn II) decreases the residence time of [18F] radiolabeled antiTAC dsFv (a fragment with high affinity for the IL-2a receptor) in the baboon kidney by altering the pharmacokinetics by preventing uptake. This will reduce the absorbed radiation dose to the kidney, thereby permitting larger injected doses in human subjects.Longer lived PET radionuclides are also under development. We are producing Ga-66, Tc-94m, and have signed a CRADA to develop a procedure to produce I-124. The Ga-66 is a long-lived positron emitter (T1/2=9.4 h) useful for labeling antibody fragments and low molecular weight proteins. Tc-94m (T1/2=52.5 min) is being used in place of Tc-99m in the traditional nuclear medicine kits to produce a myocardial imaging agent and a tumor imaging agent for PET. We also continue to produce At-211 for use in alpha particle therapy.

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Intramural Research (Z01)
Project #
1Z01CL000500-02
Application #
6103611
Study Section
Special Emphasis Panel (NPET)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Clinical Center
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Shimoji, Kazuaki; Ravasi, Laura; Schmidt, Kathleen et al. (2004) Measurement of cerebral glucose metabolic rates in the anesthetized rat by dynamic scanning with 18F-FDG, the ATLAS small animal PET scanner, and arterial blood sampling. J Nucl Med 45:665-72
Park, Luke S; Szajek, Lawrence P; Wong, Karen J et al. (2004) Semi-automated 86Y purification using a three-column system. Nucl Med Biol 31:297-301
Ma, Ying; Lang, Lixin; Kiesewetter, Dale O et al. (2004) Purification of the precursor for the automated radiosynthesis of [18F]FCWAY by counter-current chromatography. J Chromatogr A 1034:149-53
Eckelman, William C; Rice, Kenner C; Contoreggi, Carlo (2004) New tools to monitor stress using non-invasive PET imaging. Ann N Y Acad Sci 1018:487-94
Yao, Zhengsheng; Zhang, Meili; Garmestani, Kayhan et al. (2004) Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N"",N""'-tetraacetic acid-biotin. Clin Cancer Res 10:3137-46
Jagoda, E M; Vaquero, J J; Seidel, J et al. (2004) Experiment assessment of mass effects in the rat: implications for small animal PET imaging. Nucl Med Biol 31:771-9
Neumeister, Alexander; Bain, Earle; Nugent, Allison C et al. (2004) Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 24:589-91
Benson, Brenda E; Carson, Richard E; Kiesewetter, Dale O et al. (2004) A potential cholinergic mechanism of procaine's limbic activation. Neuropsychopharmacology 29:1239-50
Giovacchini, Giampiero; Lerner, Alicja; Toczek, Maria T et al. (2004) Brain incorporation of 11C-arachidonic acid, blood volume, and blood flow in healthy aging: a study with partial-volume correction. J Nucl Med 45:1471-9
Wesley, Jon N; McGee, Edwin C; Garmestani, Kayhan et al. (2004) Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At. Nucl Med Biol 31:357-64

Showing the most recent 10 out of 59 publications